Post-therapeutic acute leukemia

Auclerc, G.; Jacquillat, C; Auclerc, Marie-Françoise; Weil, M; Bernard, J

doi:10.1002/1097-0142(197912)44:6<2017::aid-cncr2820440609>3.0.co;2-a

Cited by 75 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high CR rate of 87% and long survival observed among these eight patients differ from the low CR rate of 2% to 30% and very poor survival of secondary leukemia generally. '-I9 Whereas the karyotype is a well-established important prognostic factor in de novo AML,"-" no such No. 4 CYToGENETICS IN SECONDARY LEUKEMIA -Kantarjian et al…”

Section: Discussionmentioning

confidence: 99%

The association of specific “favorable” cytogenetic abnormalities with secondary leukemia

Kantarjian

Keating

Walters

et al. 1986

Cancer

View full text Add to dashboard Cite

Eight patients with secondary leukemia and specific cytogenetic abnormalities involving inversion of chromosome 16, or translocations between chromosomes 15 and 17, or 8 and 21, are presented. Seven of them (87%) achieved complete remission with chemotherapy. The occurrence of these karyotypes, which is unusual in secondary leukemia, and the favorable response to chemotherapy are discussed in relation to the pathogenesis of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

The association of specific “favorable” cytogenetic abnormalities with secondary leukemia

Kantarjian

Keating

Walters

et al. 1986

Cancer

View full text Add to dashboard Cite

show abstract

“…We are indebted to the following physicians for providing information and slides ADDENDUM Since this manuscript was submitted for publication, several articles dealing with acute leukemia following prolonged cytotoxic agent therapy have been published (63)(64)(65). A 56-year-old white woman who was treated with radiation and combination chemotherapy (oyclophosphamide and adriamycin) for adenosquamous carcinoma of the endometrium, developed acute myelogenous leukemia 2% years later 963).…”

Section: Acknowledgmentsmentioning

confidence: 99%

“…This patient received local radiotherapy and combination chemotherapy (imidazole carboxamide, vinblastine, melphalan and BCNU) for his solid tumor. Two additional patients with non-hematopoietic cancer, one with testicular seminoma and another with endometrial adenocarcinoma developed acute nonlymphoblastic leukemia 6 and 4 years later, respectively (65). Both patients received radiotherapy and one was also treated with combination chemotherapy, including alkylating agents.…”

Section: Acknowledgmentsmentioning

confidence: 99%

Acute myeloblastic leukemia following treatment for non‐hematopoietic cancers: Report of 19 cases and review of the literature

Zarrabi

Rosner

1979

American J Hematol

View full text Add to dashboard Cite

Nineteen patients are reported who developed acute myeloblastic leukemia following treatment for a variety of solid tumors, including seminoma (four cases), melanoma (one case), and cancer of the ovary (six cases), colon or rectum (three cases), bladder (two cases), cervix, endometrium, and larynx (one case each). There were nine men and ten women, with a median age of 49.8 years (range 29 to 75). The mean interval between the diagnosis of solid tumors and acute leukemia is 5.8 years. In two patients the two diseases occurred simultaneously or within six months of each other. One patient was treated only surgically. Eight patients were treated with radiotherapy, five with chemotherapy, and five received both chemotherapy and radiotherapy. Pancytopenia was commonly noted prior to the onset of leukemia with chromosomal abnormalities observed in four cases in which a karyotype was performed. Three patients achieved complete hematological remission following antileukemic therapy. One hundred and six additional patients with non-hematopoietic neoplasms and acute leukemia are reviewed. Although acute leukemia may occur in a higher than expected frequency in patients with solid tumors because of a possible increased risk of a second neoplasm, it seems more likely that the acute leukemia is related to the radiotherapy and/or chemotherapy administered to treat the first neoplasm.

show abstract

“…In addition, it has been generally accepted that patients with secondary leukemia have a relatively poor prognosis. Early reports of patients with therapy-associated acute nonlymphocytic leukemia (t-ANLL) described median survival times of less than 3 months [1,9,10] and complete remission rates of only 10% [5,6,11]. The rising incidence of t-ANLL combined with its poor prognosis make this a serious problem of increasing magnitude.…”

Section: Introductionmentioning

confidence: 99%

Response of therapy‐associated acute nonlymphocytic leukemia to intensive induction chemotherapy

Duane

Peterson

Bloomfield

et al. 1985

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Among 31 consecutive patients who developed acute nonlymphocytic leukemia following treatment with chemotherapy or radiation therapy, 17 were treated with intensive chemotherapy aimed at inducing a complete remission. Seven of these 17 patients (41%) obtained a complete remission that ranged in duration from 2 to 11 (median 3) months. Two additional patients who failed to develop normal peripheral blood counts despite postinduction bone marrows that were normocellular and free of leukemia were classified as nonresponders. The median time to complete remission and median duration of leukopenia (WBC less than 1,000/mu 1) were 34 days and 23 days, respectively. Induction chemotherapy was complicated by fever in all patients, documented infection in six patients, and death secondary to sepsis in three. Survival of the 17 patients ranged from less than 1 to 39 (median 4) months. Patients achieving a complete remission had a median survival time of 10 months compared to 2 months for the nonresponders. The other 14 patients received only supportive care and had a median survival of 2 months. These findings indicate that therapy-associated acute nonlymphocytic leukemia (t-ANLL) can frequently respond to chemotherapy and that achieving a complete remission is associated with longer survival. Although these results are encouraging, patients with t-ANLL still have a relatively poor prognosis and efforts directed at improving treatment outcome need to be continued.

show abstract

Post-therapeutic acute leukemia

Cited by 75 publications

References 37 publications

The association of specific “favorable” cytogenetic abnormalities with secondary leukemia

The association of specific “favorable” cytogenetic abnormalities with secondary leukemia

Acute myeloblastic leukemia following treatment for non‐hematopoietic cancers: Report of 19 cases and review of the literature

Response of therapy‐associated acute nonlymphocytic leukemia to intensive induction chemotherapy

Contact Info

Product

Resources

About